GLP-1 and growth hormone peptides: separating hype from evidence

What did @makingitglowmeredith actually say?

The creator compared two growth hormone-releasing hormone (GHRH) analogs, calling them "s'moralin" (sermorelin) and "tassamoralin" (tesamorelin). They described sermorelin as a shorter peptide that gives a "gentle nudge" to the pituitary to produce more growth hormone, while positioning tesamorelin as more complex, more stabilized, with an extended half-life and longer GH pulse. They correctly noted that tesamorelin is FDA-approved, specifically for reducing visceral fat in HIV patients. They wrapped up with a personal endorsement of tesamorelin based on their own research, and the standard disclaimer that none of this is medical advice.

The video is aimed at a general wellness audience curious about peptide optimization. The creator presents themselves as an informed researcher rather than a clinician, which matters a great deal when parsing how accurate these claims actually are.

Does the science back this up?

Partially. The core pharmacological distinction between sermorelin and tesamorelin is real, but the framing oversimplifies things in ways that could mislead viewers about what these compounds actually do and who they are appropriate for.

Sermorelin is a synthetic analog of the first 29 amino acids of endogenous GHRH. It does stimulate the pituitary to release GH, and it does have a short half-life, typically under 10 minutes in circulation (Walker, 2006, Growth Hormone and IGF Research). Tesamorelin is a longer, stabilized GHRH analog with a trans-2-hexadecenoic acid group that extends its half-life and bioavailability. This is not a minor formulation tweak. It meaningfully changes how the molecule behaves. Falutz et al. (2007, New England Journal of Medicine) demonstrated that tesamorelin reduced visceral adipose tissue by roughly 15-18% in HIV patients with lipodystrophy over 26 weeks. That trial led to FDA approval under the brand name Egrifta.

Where the science gets more complicated is in the general wellness context. Neither peptide has robust RCT data supporting use in metabolically healthy adults for body composition or longevity. The GH-pulse framing sounds compelling but the downstream effects in non-deficient populations are far less established than this video implies.

What did they get wrong (or right)?

The creator got the FDA approval claim right. Tesamorelin is genuinely FDA-approved for HIV-associated lipodystrophy. That is accurate, and credit where it is due.

What they got wrong, or at least dangerously incomplete, is the implication that tesamorelin's approval and metabolic research findings translate neatly to a general optimization context. The Falutz et al. data applies to a specific patient population with a specific metabolic disorder. Extrapolating that to general wellness is a leap the data does not support.

The description of sermorelin as producing a "gentle nudge" is fair as a layperson analogy, but the claim that tesamorelin produces a "longer GH pulse" needs clarification. Tesamorelin's extended activity comes primarily from improved stability and bioavailability, not simply a longer intrinsic GH secretion window. The mechanism matters if you are trying to understand what you are putting in your body.

The creator also invites followers to share their personal "results," which in this context functions as implicit anecdotal endorsement of off-label use. That is a significant concern from a safety communication standpoint, regardless of the disclaimer appended at the end.

What should you actually know?

These are not interchangeable compounds, and they are not supplements. Both sermorelin and tesamorelin are prescription peptides in the United States. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Sermorelin has a narrower approval history and is sometimes prescribed off-label for GH deficiency in adults, but that is a clinical decision made with lab work and physician oversight, not a self-research project.

The wellness peptide market operates largely in a regulatory gray zone. Compounded versions of these peptides exist, but compounded drugs are not FDA-approved and their purity, potency, and sterility are not held to the same standard as approved drugs. Do not assume a peptide you source online is equivalent to a pharmaceutical-grade compound studied in clinical trials.

If you are interested in GH axis support for a legitimate medical reason, that conversation belongs in a clinical setting with IGF-1 levels, a medical history review, and a licensed provider. A TikTok video, including this one, is not a substitute for that evaluation.